Article Text
PDF
Statistics from Altmetric.com
Since the relationship of maternal autoimmunity and congenital heart block (CHB) was initially described in the late 1970s, investigators have attempted to identify additional factors associated with its development.1–4 Detection of CHB in the absence of cardiac structural abnormalities predicts the presence of maternal autoantibody responses against the ribonucleoproteins SSA/Ro and SSB/La in >85% of cases.5 CHB is associated with considerable morbidity and mortality, with a 17.5% case fatality rate and approximately 70% requiring permanent pacemaker placement.6 Sustained reversal of third-degree CHB has never been achieved and to date there is no approved medication for treatment or prevention of this disease. Recognising those mothers at increased risk of CHB in an offspring would provide insights into the pathogenesis of disease and help prioritise allocation of screening resources, including intense echocardiographic monitoring.
In a recent publication in Lupus Science and Medicine, Tonello et al sought to identify maternal autoantibody profiles conferring high risk for CHB.7 Importantly, all serological evaluations were done during the pregnancies. The authors report a ‘prospective’ study with inclusion of 81 consecutive pregnant patients positive for anti-SSA/Ro±anti-SSB/La antibodies enrolled at the outpatient clinic of the Rheumatology Unit of the University of Padova Medical Center. The authors report a surprisingly high occurrence rate of CHB at 19.8%. In contrast, many other studies have prospectively monitored anti-SSA/Ro patients during pregnancy and documented a rate of only 1%–2%.8–12 Additionally, in mothers with a previously affected CHB child, recurrence rates in retrospective studies have been reported at approximately 17%–18%,13–16 a rate confirmed in two prospective studies.17 ,18 Even if the authors remove the one recurrent CHB in their study, the occurrence rate would still be extremely high. In the discussion of the paper, the authors acknowledge that 13 (81.3%) of the 16 cases of CHB were referred from different rheumatology centres in Italy. Although not explicitly stated by the authors, perhaps these pregnancies were referred at the time CHB was detected. If this is correct, then what is unknown is the denominator of all anti-SSA/Ro positive pregnant women followed at these referring institutions. Thus, the occurrence rate of CHB at 19.8% is misleading. The high rate of CHB reported in the paper may raise undue concern in counselling women with anti-SSA/Ro antibodies facing pregnancy. Although the authors state that reporting on the epidemiology of CHB was not their explicit goal, if any mothers were identified to have anti-SSA/Ro simply on the basis of having a child with CHB, this is not a prospective study and may explain the finding that asymptomatic mothers appear to be at higher risk of developing CHB. This may also distort the predictive value of the antibody specificities reported.
While the inclusion criterion for the study by Tonello et al was the presence of anti-SSA/Ro antibodies, based on their figure 1, the titres (particularly anti-Ro60) appear quite low.7 It is already well known that CHB more frequently develops in mothers with high titre antibodies.19 Inclusion of mothers with low titre reactivities and thus at decreased risk of disease development is a limitation. To incrementally advance the field beyond what is already known, it would be important to enrol at the very least only women with high titre antibodies during the pregnancy under study.
Many previous studies, several with larger numbers, have addressed the identification of a high CHB risk profile.20–24 Conclusions have been varied depending on the method of antibody testing and/or design of the study. There has been particular excitement regarding the autoantibody response against the p200 epitope of Ro52 as a candidate biomarker conferring an increased CHB risk.22 ,24 Reed et al assessed umbilical blood and matched maternal sera from pregnancies of both CHB affected and unaffected siblings for reactivities against Ro60 (native antigen), full-length Ro52 (recombinant antigen), p200Ro52 and La48 (recombinant antigen).21 The authors concluded that reactivity to p200 does not confer an added risk to fetal conduction defects over full-length Ro52 or Ro60 autoantibodies. Mothers who may never be at risk for having an affected child have lower anti-Ro60 titres and may require less stringent echocardiographic monitoring compared with women with high titre autoantibodies. Unfortunately they could not identify a profile that predicted recurrent CHB.21
Clearly, as Tonello points out we need to better predict woman at the greatest risk for the development of CHB in an offspring, but we are not there yet. Antibody profiling should focus on evaluation of those mothers with high titre anti-SSA/Ro antibodies. Perhaps even more importantly we may have to accept that even the highest risk profile is not the answer but begin a more intense search for fetal factors.
References
Footnotes
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.